HAE-4 reduced both small and large parenchymal A plaques (Fig
HAE-4 reduced both small and large parenchymal A plaques (Fig. strongest genetic risk factor for late-onset AD and exacerbates the development of A pathology through several mechanisms, including affecting A aggregation and clearance (15, 16). Previously, we exhibited that passive immunotherapy targeting mouse APOE PTP1B-IN-3 or human APOE4 reduced A pathology in mice with parenchymal…